Allogene Therapeutics
ALLO
161 hedge funds and large institutions have $1.15B invested in Allogene Therapeutics in 2022 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 64 increasing their positions, 51 reducing their positions, and 29 closing their positions.
357% more call options, than puts
Call options by funds: $1.27M | Put options by funds: $278K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
38% more capital invested
Capital invested by funds: $835M → $1.15B (+$314M)
25% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 51
5.93% more ownership
Funds ownership: 64.27% → 70.2% (+5.9%)
11% less funds holding
Funds holding: 180 → 161 (-19)
55% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$48.2M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$39.8M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$33.2M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.7M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$22.5M |
| 2 |
State Street
Boston,
Massachusetts
|
-$19.7M |
| 3 |
Norges Bank
Oslo,
Norway
|
-$10.2M |
| 4 |
Renaissance Technologies
New York
|
-$8.88M |
| 5 |
Goldman Sachs
New York
|
-$8.76M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
QT
176
Quantamental Technologies
White Plains,
New York
| – | -$175K | -19,159 | Closed |
|
|
FRM
177
Fox Run Management
Greenwich,
Connecticut
| – | -$152K | -16,712 | Closed |
|
|
BAM
178
Blueshift Asset Management
Red Bank,
New Jersey
| – | -$135K | -14,811 | Closed |
|
|
ICG
179
InterOcean Capital Group
Nashville,
Tennessee
| – | -$109K | -12,000 | Closed |
|
|
PHK
180
Point72 Hong Kong
Hong Kong
| – | -$104K | -11,467 | Closed |
|
181
Walleye Trading
New York
| – | -$76K | -8,371 | Closed |
|
182
Amundi
Paris,
France
| – | -$46K | -5,076 | Closed |
|
|
ACM
183
Aquatic Capital Management
Chicago,
Illinois
| – | -$34K | -3,700 | Closed |
|
184
Allspring Global Investments
Charlotte,
North Carolina
| – | -$22K | -2,415 | Closed |
|
185
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | -$2K | -215 | Closed |
|
186
Koshinski Asset Management
Decatur,
Illinois
| – | -$1.82K | -200 | Closed |
|
|
GWS
187
Glassman Wealth Services
Vienna,
Virginia
| – | -$1K | -82 | Closed |
|
|
C
188
Covestor
London,
United Kingdom
| – | -$53 | -6 | -21% |
|
ALLO Hedge Fund Activity: Q2 2022 in Review
161 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Allogene Therapeutics (ALLO) for Q2 2022, worth a combined $1.15B — up 38% from $835M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of ALLO and 13 opened new positions — a net loss of 16 holders — while 51 trimmed existing stakes and 64 added.
The largest buyer was Woodline Partners, adding an estimated $48.2M. The largest seller was Citadel Advisors, cutting an estimated $22.5M.
- 161 institutional investors held Allogene Therapeutics (ALLO) as of Q2 2022, down from 180 in Q1 2022.
- Funds reported $1.15B of Allogene Therapeutics stock for Q2 2022, up 38% quarter-over-quarter.
- 13 funds opened new Allogene Therapeutics positions in Q2 2022 and 29 closed out, a net change of -16 holders.
- The largest Allogene Therapeutics buyer in Q2 2022 was Woodline Partners, an estimated $48.2M added.
- The largest Allogene Therapeutics seller in Q2 2022 was Citadel Advisors, an estimated $22.5M sold.
Based on aggregated 13F filings for Q2 2022.